Movement Alert｜Twist Bioscience Rises 5.05% in Regular Trading, Evercore ISI Raises Price Target to $102

Market Focus07-07

On July 7, Twist Bioscience rose 5.05% in regular trading, trading at $103.93/share, with turnover of $58.99 million.

On the news front, investment bank Evercore ISI on July 6 downgraded Twist Bioscience from Outperform to In Line, but simultaneously raised its price target sharply from $66 to $102, representing a 54.5% increase. While the rating was lowered, the significant target price upgrade reflects the analyst's reassessment of the company's long-term value potential. According to FactSet, the consensus analyst rating remains Buy with a mean price target of $87.56.

The target price revision follows a period of improving fundamentals. The company's Q2 revenue exceeded expectations with sales of $110.7 million beating estimates, and management raised full-year revenue guidance to $435-440 million versus FactSet estimates of $432.3 million. In June, Canaccord Genuity also initiated coverage with a Buy rating and $90 price target, while earlier in May, Leerink Partners upgraded the stock to Outperform with a $70 target following strong quarterly results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160826817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160826817","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Rises 5.05% in Regular Trading, Evercore ISI Raises Price Target to $102","media":"Market Focus","content":"<p><p>On July 7, Twist Bioscience rose 5.05% in regular trading, trading at $103.93/share, with turnover of $58.99 million.</p><p>On the news front, investment bank Evercore ISI on July 6 downgraded Twist Bioscience from Outperform to In Line, but simultaneously raised its price target sharply from $66 to $102, representing a 54.5% increase. While the rating was lowered, the significant target price upgrade reflects the analyst's reassessment of the company's long-term value potential. According to FactSet, the consensus analyst rating remains Buy with a mean price target of $87.56.</p><p>The target price revision follows a period of improving fundamentals. The company's Q2 revenue exceeded expectations with sales of $110.7 million beating estimates, and management raised full-year revenue guidance to $435-440 million versus FactSet estimates of $432.3 million. In June, Canaccord Genuity also initiated coverage with a Buy rating and $90 price target, while earlier in May, Leerink Partners upgraded the stock to Outperform with a $70 target following strong quarterly results.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Rises 5.05% in Regular Trading, Evercore ISI Raises Price Target to $102</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Rises 5.05% in Regular Trading, Evercore ISI Raises Price Target to $102\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 00:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, Twist Bioscience rose 5.05% in regular trading, trading at $103.93/share, with turnover of $58.99 million.</p><p>On the news front, investment bank Evercore ISI on July 6 downgraded Twist Bioscience from Outperform to In Line, but simultaneously raised its price target sharply from $66 to $102, representing a 54.5% increase. While the rating was lowered, the significant target price upgrade reflects the analyst's reassessment of the company's long-term value potential. According to FactSet, the consensus analyst rating remains Buy with a mean price target of $87.56.</p><p>The target price revision follows a period of improving fundamentals. The company's Q2 revenue exceeded expectations with sales of $110.7 million beating estimates, and management raised full-year revenue guidance to $435-440 million versus FactSet estimates of $432.3 million. In June, Canaccord Genuity also initiated coverage with a Buy rating and $90 price target, while earlier in May, Leerink Partners upgraded the stock to Outperform with a $70 target following strong quarterly results.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1160826817","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160826817","pubTimestamp":1783354100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, Twist Bioscience rose 5.05% in regular trading, trading at $103.93/share, with turnover of $58.99 million.On the news front, investment bank Evercore ISI on July 6 downgraded Twist...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"动向提示|Twist Bioscience常规交易涨5.05%Evercore ISI上调目标价至102美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On July 7, Twist Bioscience rose 5.05% in regular trading, trading at $103.93/share, with turnover of $58.99 million.On the news front, investment bank Evercore ISI on July 6 downgraded Twist Bioscience from Outperform to In Line, but simultaneously raised its price target sharply from $66 to $102, representing a 54.5% increase. While the rating was lowered, the significant target price upgrade reflects the analyst's reassessment of the company's long-term value potential. According to FactSet, the consensus analyst rating remains Buy with a mean price target of $87.56.The target price revision follows a period of improving fundamentals. The company's Q2 revenue exceeded expectations with sales of $110.7 million beating estimates, and management raised full-year revenue guidance to $435-440 million versus FactSet estimates of $432.3 million. In June, Canaccord Genuity also initiated coverage with a Buy rating and $90 price target, while earlier in May, Leerink Partners upgraded the stock to Outperform with a $70 target following strong quarterly results.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160826817","isCrawlerRequest":true}